TEVA - Teva Pharmaceutical Industries Ltd Table of Contents...

Info icon This preview shows pages 1–5. Sign up to view the full content.

View Full Document Right Arrow Icon
Teva Pharmaceutical Industries, Ltd
Image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full Document Right Arrow Icon
Table of Contents Table of Contents Issues ............................................................................................................................................... 1 Financial Analysis ....................................................................................................................... 1-2 Porters 5 Forces .......................................................................................................................... 2-4 Alternatives Identification ............................................................................................................. 4 Evaluation of Alternatives .......................................................................................................... 4-5 Recommendation ............................................................................................................................ 6
Image of page 2
Issues Since becoming a global giant, Teva is now forced to compete with a low-cost prices for innovative drugs by other emerging pharmaceutical companies. Teva must also compete with research and development from other larger pharmaceutical companies while developing their own innovative drugs. The question of expanding their scope or expanding geographically becomes an essential issue. The main issues surrounding this case can be ultimately broken down into four issue; emerging markets, valuation, political risks, and debt ratings. Like any good company should, Teva must assess the risk involved in an emerging market and build strategies to counter these threats. Differentiation will also be a challenge and a necessity in order for Teva to deliver value added product. Political risks are always present in any foreign investments and Teva must assess risks associated with its own foreign investments. In an industry dependent on good debt, Teva must consider their debt rating in an emerging market. Teva Financial Analysis Teva is a fast growing company that has doubled its sales in the past six years while maintain a good debt to capital ratio. Teva has sustained an average ROA of 7% a year over the past five years and 64% of its revenues come from North America. Teva’s Return on Equity has averaged 15.5% over the last five years doubling the ROA of their investors. In addition, Teva has experienced great profit increase from their brand name drug for multiple sclerosis, Copaxone. In 2005, Copaxone’s sales reached $1.2 billion and Teva received an estimated 55% ($647 million) of these sales through their affiliation with Sanofi-Aventis. According to the 90- 95% estimated gross margins, 10% is deducted for cost of goods sold. Research and development expenses are estimated at 14% and the Administrative, General, & Selling (AGS) 1
Image of page 3

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full Document Right Arrow Icon
Costs are estimated at 10%. The AGS may be lower due to Sanofi-Aventis having a large share of these expenses. In the table below, is an estimate of Teva’s operating margin from Copaxone
Image of page 4
Image of page 5
This is the end of the preview. Sign up to access the rest of the document.

{[ snackBarMessage ]}

What students are saying

  • Left Quote Icon

    As a current student on this bumpy collegiate pathway, I stumbled upon Course Hero, where I can find study resources for nearly all my courses, get online help from tutors 24/7, and even share my old projects, papers, and lecture notes with other students.

    Student Picture

    Kiran Temple University Fox School of Business ‘17, Course Hero Intern

  • Left Quote Icon

    I cannot even describe how much Course Hero helped me this summer. It’s truly become something I can always rely on and help me. In the end, I was not only able to survive summer classes, but I was able to thrive thanks to Course Hero.

    Student Picture

    Dana University of Pennsylvania ‘17, Course Hero Intern

  • Left Quote Icon

    The ability to access any university’s resources through Course Hero proved invaluable in my case. I was behind on Tulane coursework and actually used UCLA’s materials to help me move forward and get everything together on time.

    Student Picture

    Jill Tulane University ‘16, Course Hero Intern